๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Fatigue during preoperative chemoradiation for resectable rectal cancer

โœ Scribed by Xin Shelley Wang; Nora A. Janjan; Hong Guo; Beth A. Johnson; Martha C. Engstrom; Christopher H. Crane; Tito R. Mendoza; Charles S. Cleeland


Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
142 KB
Volume
92
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

โœฆ Synopsis


BACKGROUND.

The aim of this study was to evaluate the severity and patterns of fatigue during preoperative chemoradiation therapy for locally advanced rectal cancer and determine whether there are predictors for patients who develop severe fatigue.

METHODS.

Seventy-two patients with resectable rectal cancer received chemoradiation (total radiation dose, 45 gray/25 fractions to the pelvis; continuous infusion of 5-fluorouracil [300 mg/m 2 ]). The Brief Fatigue Inventory (BFI), a measure that categorizes fatigue severity on a 0 -10 scale, was administered weekly during treatment. Severe fatigue was defined as 7-10 on the "worst level of fatigue" item.

Demographics, disease information, toxicities, and blood counts were collected.

Descriptive statistics, repeated measure analysis of variance, and multiple regression were used to examine fatigue and its correlates.

RESULTS. Fatigue increased in 67% of patients during chemoradiation (CTX/XRT).

The mean fatigue score increased from 3.16 before treatment to 4.62 at the end of treatment. A significant linear trend suggested that fatigue progressively got worse during CTX/XRT (F ฯญ 16.497, P ฯฝ 0.001). However, 18% of patients experienced severe fatigue before CTX/XRT; this was predicted by uncontrolled pain (r 2 ฯญ 0.321; F ฯญ 16.52; P ฯฝ 0.001). During CTX/XRT, uncontrolled diarrhea was the only predictor for increased fatigue (r 2 ฯญ 0.182; F ฯญ 7.77; P ฯฝ 0.01). Approximately one-third of patients had severe fatigue, which impaired their function at the end of CTX/XRT.

CONCLUSIONS.

Preoperative chemoradiation therapy for patients with rectal cancer was associated with progressive fatigue during therapy. Based on identified predictors for fatigue, more active pain management before CXT/XRT and bowel management during CTX/XRT might reduce cancer-related fatigue in these patients.


๐Ÿ“œ SIMILAR VOLUMES


Chemoradiation for rectal cancer: Curren
โœ Michael W. Barrett ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 37 KB

The options available for the surgeon treating patients with rectal cancer have multiplied over the last decade, allowing varied approaches to the disease for individual patients. The development of effective adjuvant therapy in the form of radiotherapy and chemotherapy has led to exciting results-a

p53 gene mutation is not directly relate
โœ Ichikawa, Daisuke; Yamaguchi, Toshiharu; Shirasu, Morio; Kitamura, Kazuya; Inaza ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 386 KB ๐Ÿ‘ 2 views

Background: Several studies have recently demonstrated that apoptosis of cancer cells is triggered by diverse adjuvant cancer therapies and the induction of apoptosis correlates with the sensitivity of the primary tumor to such therapies. Methods: We investigated the factors modulating adjuvant can

Locally recurrent rectal cancer: Role of
โœ Temple, Walley J.; Saettler, Elizabeth B. ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 136 KB ๐Ÿ‘ 1 views

Locally recurrent cancer of the rectum has been under-recognized as a complication, although it affects up to 40% of patients treated with surgery alone. Even in the best centers, rates average 25%. While radiotherapy may reduce recurrence, it is now apparent that total mesorectal excision is the mo